The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
Subscribe To Our Newsletter & Stay Updated
